Skip to main content
Fig. 3 | Respiratory Research

Fig. 3

From: Immunomodulatory and clinical effects of receptor-interacting protein kinase 1 (RIPK1) inhibitor eclitasertib (SAR443122) in patients with severe COVID-19: a phase 1b, randomized, double-blinded, placebo-controlled study

Fig. 3

Time to 50% improvement in CRP levels (3 A), time to improvement of oxygenation (SpO2 /FiO2 ratio) (3B), time to liberation from supplemental oxygen (3 C), and improvement by at least two points on 7-point clinical scale (3D) for efficacy population. Event times for patients not meeting this criterion was censored at the last observation time point. For patients who died during the study without experiencing the event, the last observation collected is carried forward to the longest duration of follow-up for any patient plus 1 day. Event is defined as 50% decrease relative to baseline CRP level (3 A), presence of SpO2 ≥92% without use of any supplemental oxygen device on two consecutive days or on the day of discharge (3 C), and an improvement of at least 2 points in category of 7-point clinical scale from baseline (3D)

Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us